Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1-10 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|February 5, 2011
Molecular characterization of the cervical and systemic B-cell repertoire: Unique, yet overlapping, immune compartments of an HIV-1 resistant individualRyan G Gaudet, Felix Breden, Frank Plummer, et al.
Mabs|October 9, 2010
Metrics for antibody therapeutics developmentJanice M Reichert
Mabs|November 18, 2010
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targetingIngo Schubert, Christian Kellner, Christoph Stein, et al.
Mabs|December 3, 2010
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challengesPaulo Fontoura
Mabs|June 29, 2010
Recombinant antibodies specific for the Plasmodium falciparum histidine-rich protein 2Elisabeth Ravaoarisoa, Halima Zamanka, Thierry Fusai, et al.
Mabs|October 12, 2010
Have we overestimated the benefit of human(ized) antibodies?Daniel R Getts, Meghann T Getts, Derrick P McCarthy, et al.
Mabs|October 28, 2010
The long and winding road to antibody therapeuticsJohn McCafferty
Mabs|November 5, 2010
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseasesAlexander M Owyang, Hassan Issafras, John Corbin, et al.
Mabs|April 14, 2011
Regulatory pathways in the European UnionManuela Kohler
Mabs|April 14, 2011
Fragmentation of monoclonal antibodiesJosef Vlasak, Roxana Ionescu
Pageof 184

Showing results (1-10 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|February 5, 2011
Molecular characterization of the cervical and systemic B-cell repertoire: Unique, yet overlapping, immune compartments of an HIV-1 resistant individualRyan G Gaudet, Felix Breden, Frank Plummer, et al.
Mabs|October 9, 2010
Metrics for antibody therapeutics developmentJanice M Reichert
Mabs|November 18, 2010
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targetingIngo Schubert, Christian Kellner, Christoph Stein, et al.
Mabs|December 3, 2010
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challengesPaulo Fontoura
Mabs|June 29, 2010
Recombinant antibodies specific for the Plasmodium falciparum histidine-rich protein 2Elisabeth Ravaoarisoa, Halima Zamanka, Thierry Fusai, et al.
Mabs|October 12, 2010
Have we overestimated the benefit of human(ized) antibodies?Daniel R Getts, Meghann T Getts, Derrick P McCarthy, et al.
Mabs|October 28, 2010
The long and winding road to antibody therapeuticsJohn McCafferty
Mabs|November 5, 2010
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseasesAlexander M Owyang, Hassan Issafras, John Corbin, et al.
Mabs|April 14, 2011
Regulatory pathways in the European UnionManuela Kohler
Mabs|April 14, 2011
Fragmentation of monoclonal antibodiesJosef Vlasak, Roxana Ionescu
Pageof 184